AZD2423 + AZD2423 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nerve Pain
Conditions
Nerve Pain
Trial Timeline
Oct 1, 2010 → Apr 1, 2012
NCT ID
NCT01200524About AZD2423 + AZD2423 + Placebo
AZD2423 + AZD2423 + Placebo is a phase 2 stage product being developed by AstraZeneca for Nerve Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01200524. Target conditions include Nerve Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01200524 | Phase 2 | Completed |
| NCT01201317 | Phase 2 | Completed |
Competing Products
11 competing products in Nerve Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QUTENZA + Lidocaine + Tramadol | Astellas Pharma | Approved | 85 |
| Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Selumetinib + Sirolimus | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2/3 | 65 |
| everolimus + bevacizumab | Novartis | Phase 2 | 52 |
| Zyvox - linezolid + Matched control | Pfizer | Phase 3 | 76 |
| Pregabalin (Lyrica) + Placebo | Pfizer | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Tisseel® | Baxter | Pre-clinical | 20 |
| Processed Nerve Allograft (human) | Axogen | Phase 3 | 72 |